A MUCOLYTIC WITH ANTIINFLAMMATORY QUALITIES FOR CHILDREN SUFFERED FROM CYSTIC FIBROSIS: DORNASE ALFA

Abstract

Chronic inflammation of airways always takes place in case of cystic fibrosis. Being a powerful mucolytic, dornase alfa also has antiinflammatory and antibacterial qualities. The article gives the authors' own data on the study of the dornase alfa anti-inflammatory action acquired by the assessment of the proteolysis-antiproteolysis system indicators. It is reasonable to prescribe the drug immediately after establishing diagnosis with preventive and medical purposes and in case of complications (e. g., in case of the chronic polypous pansinusitis development). It is necessary to abide by the standards of its application along with kinesitherapy in order to achieve a full-scale medical effect. Strict compliance with the instructions on how to conduct the drug part of baseline therapy in case of cystic fibrosis is an essential condition of patients' stability and improvement in quality of their life which favor active psychological and social adaptation.

Keywords

• children
• mucoviscidosis
• dornase alfa
• chronic inflammation at mucoviscidosis
• antiinflammatory and antibacterial qualities
• mucolytic
• mucostasis
• chronic bronchitis
• chronic polypous pansinusitis
• dosage schedule